1. Home
  2. KIO vs AVXL Comparison

KIO vs AVXL Comparison

Compare KIO & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Income Opportunities Fund

KIO

KKR Income Opportunities Fund

HOLD

Current Price

$11.56

Market Cap

469.6M

Sector

Finance

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$4.02

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KIO
AVXL
Founded
2011
2004
Country
United States
United States
Employees
2400
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
469.6M
397.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
KIO
AVXL
Price
$11.56
$4.02
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$22.00
AVG Volume (30 Days)
136.5K
4.1M
Earning Date
01-01-0001
11-25-2025
Dividend Yield
10.82%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.52
$2.86
52 Week High
$13.59
$14.44

Technical Indicators

Market Signals
Indicator
KIO
AVXL
Relative Strength Index (RSI) 38.51 36.99
Support Level $11.67 $3.96
Resistance Level $11.65 $4.88
Average True Range (ATR) 0.08 0.41
MACD 0.02 0.20
Stochastic Oscillator 39.29 55.44

Price Performance

Historical Comparison
KIO
AVXL

About KIO KKR Income Opportunities Fund

KKR Income Opportunities Fund operates as a closed-end registered management investment company. It seeks to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in the portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: